Background: Nitric oxide (NO), a small effector molecule produced enzymatically from L-arginine by nitric oxide synthase (NOS), is a mediator not only of important homeostatic mechanisms (e.g., blood vessel tone and tissue perfusion), but also of key aspects of local and systemic inflammatory responses. Previous efforts to develop inhibitors of NOS to protect against NO-mediated tissue damage in endotoxin shock have been unsuccessful, largely because such competitive NOS antagonists interfere with critical vasoregulatory NO production in blood vessels and decrease survival in endotoxemic animals. Accordingly, we sought to develop a pharmaceutical approach to selectively inhibit NO production
systemic inflammatory responses. Previous efforts to develop inhibitors of NOS to protect against NO-mediated tissue damage in endotoxin shock have been unsuccessful, largely because such competitive NOS antagonists interfere with critical vasoregulatory NO production in blood vessels and decrease survival in endotoxemic animals. Accordingly, we sought to develop a pharmaceutical approach to selectively inhibit NO production in macrophages while sparing NO responses in blood vessels. Materials and Methods: The processes of cytokineinducible L-arginine transport and NO production were studied in the murine macrophage-like cell line (RAW 264.7) . A series of multivalent guanylhydrazones were synthesized to inhibit cytokine-inducible L-arginine transport. One such compound (CNI-1493) was studied further in animal models of endothelial-derived relaxing factor (EDRF) activity, carrageenan inflammation, and lethal lipopolysaccharide (LPS) challenge. Results: Upon activation with cytokines, macrophages increase transport of L-arginine to support the production of NO by NOS. Since endothelial cells do not require this additional arginine transport to produce NO, we reasoned that a competitive inhibitor of cytokine-inducible L-arginine transport would not inhibit EDRF activity in blood vessels, and thus might be effectively employed against endotoxic shock. CNI-1493, a tetravalent guanylhydrazone, proved to be a selective inhibitor of cytokineinducible arginine transport and NO production, but did not inhibit EDRF activity. In mice, CNI-1493 prevented the development of carrageenan-induced footpad inflammation, and conferred protection against lethal LPS challenge. Conclusions: A selective inhibitor of cytokine-inducible L-arginine transport that does not inhibit vascular EDRF responses is effective against endotoxin lethality and significantly reduces inflammatory responses.
INTRODUCTION
Lethal tissue injury in septic shock syndrome, a frequent complication of critical illness, causes excessive mortality in association with any number of disease states, including trauma. Septic shock syndrome and organ damage are directly attributable to the action of endogenous mediators released by macrophages activated by pathogenic stimuli such as bacterial endotoxin (lipopolysaccharide [LPS] ). These mediators include a variety of cytokines (especially tumor necrosis factor [TNF] and interleukin 1 ) and nitric oxide (1) (2) (3) (4) . When produced in smaller physiological amounts, these factors are beneficial in host defense, but when overproduced in pathological quantities, their injurious and lethal effects predominate (5) . Identification of the molecular mechanisms underlying the lethality of septic shock has led to the development of novel experimental strategies targeted against these endogenous mediators in the hope of limiting morbidity and mortality in this grave disease process.
Nitric oxide (NO) is a short-lived effector molecule that has been implicated in causing hypotension, vascular leakage syndrome, and tissue injury in septic shock (for review see Refs. 6 and 7). It is enzymatically produced from Larginine by nitric oxide synthase (NOS), an enzyme present as various inducible and constitutive isoforms in smooth muscle, neurons, endothelial cells, macrophages, and other cell types. A number of agents that competitively inhibit NOS [(e.g., NG_ methyl-L-Arginine (L-NMA) and NG-nitro-L-arginine methyl estes (L-NAME) )] have been developed for use as anti-inflammatory agents. These have been shown to be effective in preventing, for instance, the inflammation associated with experimental adjuvant arthritis, and the development of immune complex glomerulonephritis in MRL-lpr/ lpr mice (8, 9) . Unfortunately, these agents are deleterious when admninistered in experimental endotoxic shock, where they actually decrease survival relative to vehicle-treated controls (10) (11) (12) (13) (14) . Recent evidence reveals that this increase in mortality is a side effect of the non-selective action of these compounds, which indiscriminately inhibit vital NOS activity in blood vessels (termed endothelium-derived relaxing factor [EDRF]), rather than the desired action of inhibiting macrophage-derived NO (13) . As a result, local vasoconstriction cannot be relieved by EDRF, reducing blood flow to critical tissues, limiting oxygen delivery to tissues, and worsening ischemic organ damage already present during shock (13, 15) . Thus, the presently available NOS inhibitors further compromise organ perfusion during endotoxic shock and hasten rather than allay mortality in this condition.
Based in part on these observations, there is widespread interest in the identification of experimental agents to inhibit the production of NO in macrophages and other cells, but preserve the vasoregulatory NO responses in blood vessels. In the present study, we designed and developed a novel compound that limits L-arginine uptake by macrophages and inhibits their NO production. This agent (CNI-1493) selectively inhibited cytokine-inducible L-arginine uptake in macrophages, but did not inhibit EDRF activity in vivo. Moreover, it was effective in preventing carrageenan-induced inflammation and conferred protection against endotoxin lethality. We conclude that novel compounds that inhibit cytokine-inducible L-arginine transport activity may be effective therapeutic agents against inflammation and shock.
MATERIALS AND METHODS

Synthesis of CNI-1493
CNI-1493 (N,N'-bis [3, 5-diacetylphenyl] decanediamide tetrakis[amidinohydrazone] tetrahydrochloride) was prepared by reacting 3,5-diacetylaniline (16) with sebacoyl chloride in dichloromethane containing pyridine. The resulting tetraketone was collected by filtration, and reacted with aminoguanidine hydrochloride in aqueous ethanol at reflux. The final product was purified from the reactants by crystallization, and subjected to elemental analysis, proton NMR, and melting point determinations to confirm structure and assess purity prior to use. These data indicated .98% purity, with the identity of the principal contaminant as the corresponding tris-aminohydrazone. (18) . There was no significant efflux of transported label into the washes (not shown). In agreement with other studies in macrophages, 85% of Larginine is metabolized via arginase to ornithine and urea, and the remaining 15% via NOS to NO and citrulline (17) .
Determination of NOS Activity in Stimulated Macrophage Lysates
Activity of NOS present in activated macrophage lysates was measured by determining the conversion of radiolabeled L-arginine into citrulline by a modification of previously described methods (20) . Briefly, macrophages were stimulated with IFNy and LPS (as outlined above). After 18 hr, the cells were washed with PBS and lysed by three cycles of freeze/thawing in HEPES (20 mM) containing sucrose (0.32 M), EDTA (1 mM), DlT (1 mM), glycerol (5%), protease inhibitors (PMSF, leupeptin, aprotinin, and iodoacetamide), pH 7.2. The lysate was pelleted by centrifugation (100,000 X g) for 30 min. To measure NOS activity in the lysates, 300 ,ul of lysate was added to 60 ,lI of a reaction mixture containing NADPH (2 mM), CaCl2 (0.45 mM), Larginine (50 ,uM), calmodulin (10 ,ug/ml), [3H]-L-arginine (1 ,uCi/ml), and Tween (20%). After 45 min at 37°C HEPES buffer (2 ml) was added and the labeled L-arginine and citrulline separated by chromatography (DOWEX AS 5OW column). NOS activity is expressed as nanomole citrulline per minute per milligram total protein.
Determination of EDRF Activity In Vivo Female Sprague-Dawley rats (225-250 g body wt) were anesthetized with nembutal (50 mg/kg, i.p.), a tracheostomy tube inserted, and the carotid artery and jugular vein cannulated by standard methods using polyethylene tubing (PE 50) (21) . Blood pressure was recorded continuously with a pressure transducer and recorder (Model RS-3200; Gould, Inc.). In the experiment shown here, animals received a single sterile intra-arterial dose of either NG-methyl-L-arginine (50 mg/ kg; Sigma), CNI-1493 (10 mg/kg), or vehicle (0.4 ml). Acetylcholine diluted in LPS-free sterile water was administered via the jugular vein cannula at the doses indicated. The solutions were diluted to provide a constant injectable volume of 1 ml/kg body wt. The hypotensive (EDRF) response was measured as the decline in mean arterial blood pressure recorded 30 sec after administration of acetylcholine. The number of animals studied at each dose of acetylcholine was four to six for each experimental condition. The data are expressed as the mean ± standard error.
Carrageenan-Induced Footpad Inflammation Paw edema was induced by injecting 1% Lambda-carrageenan (50 gl; Sigma) in HEPES 25 mM, pH 7.4, into the plantar surface of the left hindpaw of female C3H/HeN mice (20-25 g body wt) (22) . The right hindpaw was injected with HEPES alone (50 ,ll). At 1.5 hr prior to paw injection, CNI-1493 was administered intraperitonealy at the doses indicated in a volume of 0.2 ml/animal. Three hours after paw injection, the thickness of the carrageenan-and saline-injected paws was measured using a caliper, and the data expressed as the difference between the diameters of the two paws. Data shown are the mean ± standard error of the differences between paws; four animals were studied per dose of CNI-1493. At the conclusion of the experimental period, animals were euthanized and the paw tissues fixed with 10% formalin, sectioned, and stained with hematoxylin and eosin for histological study.
Endotoxin Lethality Studies These studies were performed by modification of a recently published protocol (23) . Briefly, BALB/c mice (19-21 g ) were housed in a climate-controlled, 12-hr light-dark cycled facility for at least 2 weeks after arrival. On the morning of the experiment, mice were given either CNI-1493 (1 mg/kg, i.p.), NG-methyl-L-arginine (50 mg/kg, i.p.), or vehicle alone. LPS (E. coli 0111: B4; Sigma) in a dose of 13 .75 mg/kg, i.p. (0.2 ml/mouse) was given 90 min after the experimental agents. Stock LPS solutions (10 mg/ml) were sonicated initially for 20 min, diluted in LPS-free water (1.375 mg/ml), then sonicated again for 10 min immediately prior to injection. All experiments consisted of 10 animals per group, and similar results were obtained at least twice for each condition.
RESULTS
Macrophages Rely on Extracellular LArginine as Substrate for NOS Synthase It is widely known that murine macrophages produce copious quantities of NO after stimulation with LPS and IFN-y (17, (24) (25) (26) (27) (28) ng/ml) and measured the resultant cytokinestimulated NO production by the accumulation of nitrite in the conditioned medium. In agreement with others (17), we first ascertained that extracellular L-arginine availability was rate limiting for macrophage NO production (Fig. 1) . Cytokine-stimulated macrophage NO production was significantly attenuated when the culture medium was depleted of L-arginine, but was restored when L-arginine was present at physiologically relevant concentrations (50-150 ,uM) (Fig. 1) . Although macrophages are known to possess the enzymatic machinery necessary to convert glutamine or citrulline into L-arginine for NO synthesis (29) (30) (31) (32) (33) (34) (35) (36) , the present data give evidence that macrophages rely principally on exogenous L-arginine to produce significant amounts of NO. Increased L-Arginine Transport in Activated Macrophages Provides Substrate for NOS In agreement with others (18, 19, 33, 35) , we showed that macrophages activated by LPS/IFNy increase L-arginine uptake to provide substrate for NO production (Fig. 2) . L-arginine transport in macrophages was increased shortly after mac- rophages were stimulated and remained elevated for more than 24 hr (Fig. 2) . Since exogenous L-arginine availability is rate limiting for macrophage NO production (above), and L-arginine transport is stimulated during macrophage activation, we reasoned that an inhibitor of L-arginine transport had the potential to inhibit macrophage NO production. Moreover, since endothelial cells are dependent upon neither extracellular Larginine nor L-arginine transport to produce NO (29, 30) , this strategy could be expected to selectively inhibit NO production in macrophages, while preserving endothelial NO production in blood vessels, measured as EDRF activity. (more properly termed amidinohydrazone) functions and the guanidinium group of L-arginine (Fig. 3) . This tetravalent guanylhydrazone compound, termed CNI-1493, inhibited cytokine-inducible L-arginine transport when added to the culture medium of macrophages that had been stimulated 8 hr previously with LPS/IFNy, and thus were activated to transport L-arginine (Fig. 4) . There was a CNI-1493 dose-dependent inhibition of L-arginine transport; the I.C.50 of CNI-1493 against L-arginine transport in these postactivation experiments was 59 ± 15 ,uM, a (Fig. 7) . Blood pressure responses to acetylcholine (an EDRF-dependent vasodilator) were measured continuously in pentobarbital-anesthetized rats before, during, and after administration of CNI-1493, L-NMA, or vehicle only. As expected from previously published data (39) , the EDRF response was inhibited by L-NMA, as evidenced by attenuated blood pressure responses in L-NMAtreated animals compared with vehicle-treated controls (Fig. 7) . Moreover, in agreement with its known vasoconstrictive properties, we observed that L-NMA caused transient hypertension (data not shown) (13, 39, 40) . In contrast, CNI-1493 did not suppress acetylcholine-induced blood pressure changes or cause hypertension (Fig. 7) .
CNI-1493 Prevents Carrageenan-Induced Inflammation The effectiveness of CNI-1493 in suppressing NO production while preserving EDRF activity prompted us to test its effects in murine models of inflammation. We first utilized a carrageenaninduced paw edema model that has been used for more than 30 years as a screening assay for the development of anti-inflammatory compounds (22) . Mice received injections of carrageenan into the right hind paw and saline vehicle alone into the left paw. The inflammatory response to carrageenan caused significant paw swelling within 3 hr in controls as measured by an increase in the diameter of the carrageenaninjected footpad (Fig. 8) . CNI-1493 administered intraperitoneally at various doses (Fig. 8) prevented the development of carrageenan-induced paw swelling. Histological examination of carrageenan-inflamed paw tissue revealed marked subcutaneous edema and moderate to severe neutrophil infiltration (Fig. 9 a and b) . Polymorphonuclear leukocytes were observed to be marginated around dilated capillaries in the soft tissues. CNI-1493 conferred significant protection against the development of this subcutaneous edema and neutrophil recruitment ( Fig. 9 
DISCUSSION
These studies give direct evidence that a novel compound (CNI-1493) that inhibits cytokine-inducible L-arginine transport in macrophages is effective in preventing NO production, carrageenan-induced inflammation and LPS lethality. To our knowledge, this is the first compound to target macrophage NO production but preserve EDRF activity in blood vessels, thereby offering protection against lethal endotoxic shock and organ damage.
CNI-1493 Prevents Macrophage Activation An unexpected but important finding from these experiments is our observation that CNI-1493 is an extremely potent inhibitor of LPS-induced activation of macrophages. These results are somewhat analogous to the actions of glucocorticoids, which effectively prevent macrophage activation when administered before LPS (as measured by NO production), and prevent both carrageenan-induced inflammation and LPS lethality. While the present data give direct evidence that CNI-1493 is an inhibitor of cytokineinducible L-arginine transport in macrophages, it is unclear whether its effect as a transport inhibitor accounts directly for its suppression of macrophage activation. The cytokine-inducible L-arginine transporter in macrophages has been identified as , and it is plausible that CNI-1493 pretreatment may inhibit the earliest population of MCAT-2b transporters to be induced following cytokine treatment. This early interference might, in turn, interrupt any NOdependent "feed forward" signals controlling further up-regulation of the cytokine-inducible component of arginine transport and thus potently inhibit total NO production. Another possibility is that CNI-1493 acts at another site in the signaling process of macrophage activation, perhaps by down-regulating cytokine production. 
